Shares of Eliem Therapeutics fell more than 50% Monday after the company reported disappointing clinical data. Its compound to treat pain, ETX-810, failed to show a benefit over placebo in… Read More
When Juno Therapeutics launched in 2013, cell therapy was a nascent field. Early clinical studies were showing dramatic rates of remissions in leukemia patients treated with their own immune cells,… Read More